%PDF-1.4
%
74 0 obj
<>
endobj
71 0 obj
<>
endobj
180 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2003-09-08T16:36:27Z
2024-03-28T06:23:50-07:00
QuarkXPressª 4.11: AdobePS 8.8.0 (301)
2024-03-28T06:23:50-07:00
application/pdf
Heather
2002-223.oct
uuid:1e9c8958-1dd2-11b2-0a00-ac0927bd3700
uuid:1e9c895b-1dd2-11b2-0a00-5b0000000000
endstream
endobj
60 0 obj
<>
endobj
61 0 obj
<>
endobj
75 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 42 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 44 0 R/Type/Page>>
endobj
4 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 46 0 R/Type/Page>>
endobj
12 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 48 0 R/Type/Page>>
endobj
20 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 50 0 R/Type/Page>>
endobj
28 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 52 0 R/Type/Page>>
endobj
36 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 54 0 R/Type/Page>>
endobj
209 0 obj
[214 0 R]
endobj
210 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
0 0 0 0 k
/GS1 gs
420 777 137 -27 re
f*
0 0 0 1 K
54 54 m
558 54 l
S
BT
0 0 0 1 k
/T1_0 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 420.3613 35.9844 Tm
(The Journal of Rheumatology 2003; 30:10)Tj
0 Tc 0 Tw -45.7952 -0.0313 Td
(2192)Tj
ET
0 0 0 0 k
/GS0 gs
109.25 59.1 396.47 -10.84 re
f*
0.5 w
109.25 59.1 396.47 -10.84 re
S
BT
0 0 0 1 k
/GS1 gs
/T1_1 1 Tf
-0.00011 Tc -0.0074 Tw 10 0 0 10 66 713.1616 Tm
[(Not surprisingly)65 (, hip replacement is positively associated)]TJ
0.01691 Tc 0.358 Tw -1.2 -1.2 Td
(with worse BASFI and MRS scores, as in previous)Tj
-0.00011 Tc 0 Tw 0 -1.2 TD
(reports)Tj
0 Tc 6.5 0 0 6.5 81.7612 692.4616 Tm
(2,22)Tj
10 0 0 10 93.1361 689.1616 Tm
(.)Tj
-0.00011 Tc 0.01511 Tw -2.7136 -1.2 Td
[(Among the measures for mobility and posture, finger)20 (-to-)]TJ
0.1088 Tw -1.2 -1.2 Td
(floor distance, cervical rotation, and chest expansion were)Tj
0.06441 Tw T*
[(identified as significantly influencing BASFI. )18 (The occiput-)]TJ
0.022 Tw T*
(to-wall distance and the modified Schober were not statisti-)Tj
0.0199 Tc 0.3709 Tw T*
[(cally significant. Clearly)65 (, given the constraints of a)]TJ
0.37469 Tw T*
[(cross-sectional study)65 (, stronger evidence can only be)]TJ
-0.00011 Tc 0.3454 Tw T*
(obtained through prospective longitudinal studies. Such)Tj
0.12691 Tw T*
[(cohort studies are under way)65 (, but it may take many years)]TJ
0.02499 Tw T*
(before firm conclusions can be drawn.)Tj
0.0304 Tw 1.2 -1.2 Td
(Modeling \321 as done in our study \321 is a formal process)Tj
0.1008 Tw -1.2 -1.2 Td
(and the results must be interpreted on the basis of clinical)Tj
0.01379 Tw T*
[(experience and knowledge. )18 (The primary aim of modeling is)]TJ
0.0453 Tw T*
(to confirm \(or reject\) empirical perceptions and hypotheses)Tj
-0.026 Tw T*
[(as well as to reveal relationships between various factors. )18 (T)70 (o)]TJ
0.11571 Tw T*
(validate our results of modeling, various types of variable)Tj
0.2011 Tw T*
(selection procedures were performed, ensuring that more)Tj
0.291 Tw T*
(than random relationships were detected. In addition, a)Tj
0.2791 Tw T*
(comprehensive search for violations of assumptions has)Tj
0.0578 Tw T*
[(been performed. )18 (This study involved a rather lar)18 (ge number)]TJ
0.12131 Tw T*
(of patients and provides ample evidence in support of the)Tj
0.02499 Tw T*
(results within the limitations discussed.)Tj
0.32899 Tw 1.2 -1.2 Td
(The moderate correlation between BASFI and MRS)Tj
0.007 Tw -1.2 -1.2 Td
[(suggests that the 2 are not interchangeable. )18 (They apparently)]TJ
0.02499 Tw T*
[(partly reflect dif)18 (ferent conditions.)]TJ
0.0558 Tw 1.2 -1.2 Td
(Disability and restriction in body function are important)Tj
0.03281 Tw -1.2 -1.2 Td
(outcomes. Our findings can contribute to understanding the)Tj
0.01331 Tw T*
(factors that influence disability and restricted body function)Tj
0.01489 Tc 0.36 Tw T*
[(in patients with )55 (AS. Reliable prediction of longterm)]TJ
-0.00011 Tc 0.0255 Tw T*
(outcome is badly needed to identify patients at highest risk,)Tj
0.02499 Tw T*
[(who may benefit from tar)18 (geted interventions.)]TJ
/T1_2 1 Tf
0 Tw 0 -2 TD
(ACKNOWLEDGMENT)Tj
/T1_1 1 Tf
0.1013 Tw 8 0 0 8 54 299.1616 Tm
[(The authors are indebted to all medical staf)18 (f of the Gasteiner Heilstollen)]TJ
0.01601 Tw 0 -1.25 TD
(Hospital for their continuous help in data collection, but especially wi\
sh to)Tj
0.02499 Tw T*
(thank all participating patients.)Tj
/T1_2 1 Tf
0 Tw 10 0 0 10 54 255.1616 Tm
(REFERENCES)Tj
/T1_1 1 Tf
0.02499 Tw 8 0 0 8 61 245.1616 Tm
[(1.)-875 (Khan MA. )55 (Ankylosing spondylitis: clinical aspects. In: Calin )55 (A,)]TJ
1.675 -1.25 Td
[(T)70 (aurog JD, editors. )18 (The spondylarthritides. Oxford: Oxford)]TJ
T*
(University Press; 1998:27-40.)Tj
-1.675 -1.25 Td
[(2.)-875 (Amor B, Santos RS, Nahal R, Listrat )18 (V)129 (, Dougados M. Predictive)]TJ
1.675 -1.25 Td
(factors for the longterm outcome of spondyloarthropathies. )Tj
T*
(J Rheumatol 1994;21:1883-7.)Tj
-1.675 -1.25 Td
[(3.)-875 (Calin )55 (A, Kennedy LG, Edmunds L, )18 (W)40 (ill R. Familial versus)]TJ
1.675 -1.25 Td
[(sporadic ankylosing spondylitis. )18 (T)70 (wo dif)18 (ferent diseases? )55 (Arthritis)]TJ
0 Tc T*
(Rheum 1993;36:676-1.)Tj
-0.00011 Tc -1.675 -1.25 Td
[(4.)-875 (V)111 (an der Linden S. )55 (Ankylosing spondylitis. In: Kelly )18 (WN, Harris)]TJ
1.675 -1.25 Td
[(ED, Ruddy S, Sledge CB, editors. )18 (T)70 (extbook of rheumatology)65 (.)]TJ
T*
(Philadelphia: Saunders; 1997:969-82.)Tj
31.325 72.421 Td
[(5.)-875 (W)80 (orld Health Or)18 (ganization. International Classification of)]TJ
1.675 -1.25 Td
[(Functioning, Disability and Health. )55 (A)74 (vailable from:)]TJ
T*
(www3.who.int/icf/icftemplate.cfm [Cited May 12, 2003].)Tj
-1.675 -1.25 Td
[(6.)-875 (Calin )55 (A, Garrett S, )18 (Whitelock H, et al. )55 (A)-220 (new approach to defining)]TJ
1.675 -1.25 Td
(functional ability in ankylosing spondylitis: the development of the)Tj
T*
[(Bath )55 (Ankylosing Spondylitis Functional Index. J Rheumatol)]TJ
0 Tc 0 Tw T*
(1994;21:2281-5.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(7.)-875 (Falkenbach )55 (A, Curda B. )18 (V)111 (erification of diagnosis in patients)]TJ
1.675 -1.25 Td
(presenting for out-of-town outpatient rehabilitation [German].)Tj
T*
(\205sterr Z Phys Med Rehabil 1999;9:123-7.)Tj
-1.675 -1.25 Td
[(8.)-875 (V)111 (an der Heijde D, Calin )55 (A, Dougados M, Khan MA, van der)]TJ
1.675 -1.25 Td
(Linden S, Bellamy N. Selection of instruments in the core set for)Tj
T*
[(DC-AR)60 (T)74 (, SMARD, physical therapy)65 (, and clinical record keeping in)]TJ
T*
[(ankylosing spondylitis. Progress report of the )55 (Assessments in)]TJ
T*
[(Ankylosing Spondylitis )18 (W)80 (orking Group. J Rheumatol )]TJ
0 Tc 0 Tw T*
(1999;26:951-4.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(9.)-875 (Falkenbach )55 (A, Herold M. Unconventional medicine in Central)]TJ
1.675 -1.25 Td
[(Europe: a misuse of public health insurance? J )55 (Altern Compl Med)]TJ
0 Tc 0 Tw T*
(1999;5:479-81.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(10.)-875 (V)60 (iitanen JV)129 (, Kautiainen H, Kokko ML, )55 (Ala-Peijari S. )55 (Age and)]TJ
2.175 -1.25 Td
(spinal mobility in ankylosing spondylitis. Scand J Rheumatol)Tj
0 Tc 0 Tw T*
(1995;24:314-5.)Tj
-0.00011 Tc 0.02499 Tw -2.1381 -1.25 Td
[(1)37 (1.)-875 (T)70 (aylor )55 (AL, Balakrishnan C, Calin )55 (A. Reference centile charts for)]TJ
2.1381 -1.25 Td
[(measures of disease activity)65 (, functional impairment, and metrology)]TJ
T*
[(in ankylosing spondylitis. )55 (Arthritis Rheum 1998;41:1)37 (1)37 (19-25.)]TJ
-2.175 -1.25 Td
[(12.)-875 (Boonen )55 (A, Chorus )55 (A, Miedema H, et al. )18 (W)40 (ithdrawal from labour)]TJ
2.175 -1.25 Td
(force due to work disability in patients with ankylosing spondylitis.)Tj
0 Tc T*
(Ann Rheum Dis 2001;60:1033-9.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(13.)-875 (W)80 (ard MM, Kuzis S. Risk factors for work disability in patients with)]TJ
2.175 -1.25 Td
(ankylosing spondylitis. J Rheumatol 2001;28:315-21.)Tj
-2.175 -1.25 Td
[(14.)-875 (Feldtkeller E, Bruckel J, Khan MA. Scientific contributions of)]TJ
2.175 -1.25 Td
(ankylosing spondylitis patient advocacy groups. Curr Opin)Tj
T*
(Rheumatol 2000;12:239-47.)Tj
-2.175 -1.25 Td
[(15.)-875 (Barlow JH, Macey SJ, Struthers GR. Gender)40 (, depression, and )]TJ
2.175 -1.25 Td
[(ankylosing spondylitis. )55 (Arthritis Care Res 1993;6:45-51.)]TJ
-2.175 -1.25 Td
[(16.)-875 (Zink )55 (A, Braun J, Listing J, )18 (W)80 (ollenhaupt J. Disability and handicap)]TJ
2.175 -1.25 Td
(in rheumatoid arthritis and ankylosing spondylitis \321 results from)Tj
T*
(the German rheumatological database. German Collaborative)Tj
T*
(Arthritis Centers. J Rheumatol 2000;27:613-22.)Tj
-2.175 -1.25 Td
[(17.)-875 (Uhrin Z, Kuzis S, )18 (W)80 (ard MM. Exercise and changes in health status)]TJ
2.175 -1.25 Td
[(in patients with ankylosing spondylitis. )55 (Arch Intern Med)]TJ
0 Tc 0 Tw T*
(2000;2:2969-75.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(18.)-875 (Guillemin F)80 (, Briancon S, Pourel J, Gaucher )55 (A. Long-term disability)]TJ
2.175 -1.25 Td
(and prolonged sick leaves as outcome measurements in ankylosing)Tj
T*
[(spondylitis. )55 (Arthritis Rheum 1990;33:1001-6.)]TJ
-2.175 -1.25 Td
[(19.)-875 (Falkenbach )55 (A, Schuh )55 (A, )18 (W)40 (igand R. Pain in ankylosing spondylitis)]TJ
2.175 -1.25 Td
[(\321 the impact of the weather)55 (. Int J Environ Health Res 1998;8:85-9.)]TJ
-2.175 -1.25 Td
[(20.)-875 (Challier B, Urlacher F)80 (, )18 (V)111 (ancon G, Lemelle I, Pourel J, Guillemin F)80 (.)]TJ
2.175 -1.25 Td
[(Is quality of life af)18 (fected by season and weather conditions in )]TJ
T*
(ankylosing spondylitis? Clin Exp Rheumatol 2001;19:277-81.)Tj
-2.175 -1.25 Td
[(21.)-875 (Falkenbach )55 (A, Griessmayer H, )18 (T)35 (ripathi R. )18 (The impact of a positive)]TJ
2.175 -1.25 Td
(family history on the prognosis in patients with ankylosing)Tj
T*
[(spondylitis [German]. )18 (W)40 (ien Klin )18 (W)80 (ochenschr 1998;1)37 (10/1)37 (1)37 (1:20-2.)]TJ
-2.175 -1.25 Td
[(22.)-875 (Brophy S, Calin )55 (A. )55 (Ankylosing spondylitis: interaction between)]TJ
2.175 -1.25 Td
(genes, joints, age at onset, and disease expression. J Rheumatol)Tj
0 Tc 0 Tw T*
(2001;28:2283-8.)Tj
ET
0 0 0 0 k
408 770 150 -25 re
f*
Q
Q
q
0 0 612 792 re
W n
BT
0 0 0 rg
ET
/GS2 gs
BT
/T1_3 8 Tf
117.48 51 Td
(Personal, non-commercial use only. The Journal of Rheumatology Copyrig\
ht \251 2003. All rights reserved.)Tj
ET
Q
BT
0 g
/GS3 gs
/T1_4 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS3 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS3 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
54 0 obj
<>stream
8;Z\7>B0g##ikn#j>rj2%?f?$=.Gn+q:Kj'(6A[O;11#T&Q'uQ\Ie'cNdMo5T::e@
32fCq=qrUgoV'c7Ys7qKeZ$2NiXH$\98dOEB*`KLJtaMD.XH*Wf2_EW9T)Mk7t4T3
?^H?9-rnh]Lr(cG+B$0X:XEJWF_tcV7l.TYR/ZBF!F[MC[*=]O8?a8J8SGdico$]G
P@agB$\`Ya6]B3sTHet;Th[:2c//:>K)/Fg+acs[M&hIfniTA-0J4WAo6&HZ>fG.C
i7))\d9IFRlb)W)\q\h4;4;=MEZa=Bg1`+ppJlsL`R`HXe^a@CI:1++^XpHQp@X*B
g0&lf-!,t>2T8dV+:'EK;]Y8iYUn\"NYY4ud0a0XX$K&K.f_Ja[9rd)=d?_HZ)"96
SHbq$e0cp-7?#):Zlf-1)d\u!@+l9j7Y.]TTC>:#-S4ZH@NC/WqIHf#39J]"301R,
dE;LSb/'U%$^$sh-fWN[4X=.$"!F&PoWcMfao3\(!/gHcTYVhBqVttYc
RF:T/'kJj8EU+b4Dpk;.eRZUK]@=]B!VGfeO+[gW^?=/m8u&b@S:]M8fkU(@&b^o8
=VHJOo6b;5Mam9j'cY!9Vc_4d*i5VdHL8+)BX2PXJkRBF6FZ.F2nAEAn_0H1$ikg:e@#~>
endstream
endobj
58 0 obj
[/Indexed/DeviceRGB 255 57 0 R]
endobj
57 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
81 0 obj
<>
endobj
86 0 obj
<>
endobj
39 0 obj
<>
endobj
118 0 obj
<>
endobj
186 0 obj
<>
endobj
40 0 obj
<>
endobj
41 0 obj
<>stream
H\TkPWq辰=35X*$A㋸$Aad̠{@TĨBT$%겻jVŵ͊1k-anש[|Q*)Je軋VLiqc!j88~ȩQAnhB(EYPAF
J';>czxBiv)s#gO8WsּLU`N>-/3c^k4eL@Toy|ZF)[I%07S>͜{VC!7dZ_ޕYBZbB1VL
RT)"QD Q)zcOò]W*U]z'hOC*z@Ϣ@Z9.ѦRj֏~AxxF>e)6>b}֞l ޛˮ+,]\- `8R{!-3/F*$c5FOe]t4]6`'e-r2(IIhk:uPBe7jtGzGZ "rxpX";K]8
4H=^v|@},[O+Z#!s4鷇z "GIKh;%0 '48݉FL\ 59Sa<{ݯcD#A>#mCkrObv%^PM>VK]S>NI{LRUg67,g,}[e@I@"-hV.@t{OyrRJٷO\݂)Q= ̳`;xc۶rhB3@\}OW9U Fګ6ob7ҁdp~"\(4f}?G'M"?kiaL;8&o5x!6۪M®|wL+ qh,d馢YQX3|(
>
xkL6`~NqA'U;l[Up'z cS
SyÓuKX<&1OyzOs:+`& KvpMcZmGx8?Yv\g9p3Fc6߁ \q<1$HY`0WN6×Za"D37G(>4Ux{ߝd20,Չx]SWT:i27!
9Ml zo$=i
HjȰMm6PJ1h-0(ϼeq\rjl&d춾n*yGp}dĦ3cY#][^Qw/-$]~ e~:\a?t{kM:NYrVJW4DVmV'WOK>YR#څT#zZq<8POXqrDm?W
Lѩ/Gj05d/D7N4ܑ={709xHLn٥Nmߝgut'սU*ӅS\yntt-[ʡ
SnZ38M.]eO~[!ծj|[-[1
4,4Deӯ״oU#H^1e7|7Z#B
|1"t=#Q0 o5
endstream
endobj
87 0 obj
<>
endobj
112 0 obj
<>stream
H|TTga$j8 LXE@|`*>v!j $Dy("
AވQV@EZWtg`]-۽gw=;ww]p딉
ݬ5XSF183͂%D;ߒm/R-)sؔ;HUnsk[Rd3be{v?NQ![KQ$dձd&9&E&TqN)ZeJ,FHINi6V*՚tBTI)Y.uNIV*tayمq0g'c#[l1%i0,
`~+2aal1#{x>~
ZD[xBIDe=M'_s8^:%w/<7^ ''MlIa|~-7.bx+V_UM^azIDm;E'w23xח" W%'aBeT
47p;m]bT$':aM*qBjAETvJH)FV6\sK,e8J|Pt*Ta!´=SVEZQϠhn@,o %bPts]T2&GWrD\\{K:^*С@Ԉ?%:+tOfpzD<\<
lJȧD
goihDQqlf8Ds/ܷ ϒ M8(% &M0G C,^{V8@yXO+%fiS
*T0yWFAsP/u@_m1ï ;OZ4!7=ˋp
l; A"pE.o=DAnقUNr}fo.
q%{K}iAC|N\7_>}EpF&&oWM;qw E(@GpS)E#L1uŖb-f~:iRtw#KeҐ-]iwl]?,ˈ 71]"`xG3B' 21FCg |ޙ_pP߇դ`D#c517c
6q.@EpvdfpCP_/IhJ\N
0>GS.9@FiFfy?C#V:|MޮQHN}C?*n_P"EK7Wp`BT7}Ri9V@1dG2k ]T7Uz
lh
ђw)QݦC}uO\",*(̛F7ocGo-针ǩ%tO{;m\"6,4Q"H={ZT]OIu)X]ڟN}k(X)F7ryU>$ae]<肧fۚxSx8Ku@Ċ"dznLQ"-OU*;ѷYfeݕߙm)AMR+UM5u5h lMx-G0uM}f8WCDu%2`0bP$)bI!9H]#l oѪaQ+Pg.j#BOMq\XUYG$Y{y3ZKh6])QqO, jJUttMeCڠ
<"1F(2|aOqPԇ]`C9W,n8s)4k6oUT];50bZÚ8!LnXku"/xw5UTTDa
E &(r VVEueu}=_B]?I;}39kGni_@~kZ%ȟ`=b7b
5a;S*=!0Q:6-`STJI]X6(NQ'?|O薩T/ttk`1DcEy->[-da_r6KtfнaWmTR3/t(vNˊvFy=v
^3A0 RNwQk %2?jL?}1b=,)).BJ)ϴg)εh+>0οH(ac`
C
hW7n\)6-
zN:E/+dD!HBd/sMYH?&066'0,x6wh/;t`#!7(t_*`ι>dS&Hu\䆦'Gp)sBב粢 ¿A$aS༺*$ڐrK
}`"Y4ŹD1ek)]]1ɭnP#$Jhu023tf͖LaRCMV~ē1^`ҔH?HH\]>,B}J>D4&2jS#&PoXY0RH/4IIfb{VJ%áYop#c@F\ź/;#h;#)K4$~:5fTIڽaEOML'(p"Sgn1SdsIO^e,QNpd2ۖ{Z56 +U[}Wm3lX,:~Bvl17*Nr+*[}7=`ȣF7sC"ŕϛEKQij}Se,ж(zXGƀp죙ߴ$̐WҖVMb)e$m}8*I4>$W`n6UH87wp{
\![7feQ2v}'N!oI?]>[;h7qtPD(Ky#! I$D H">V
ZfnWls;t:N=qKlʴXVj[@F{BoN`,plq.W_T60El9AMc͢ĤpѓolzZv:8M2hPm\H`RvIDK~4gs %5ؠ֟"(<Ҹ
&l]r#|nK-?%.S-r;ќ.ki@84؎c,ۏ-HQNv{rw͜Hq7rߛt幬\kkGpjICI
н{ScOC;yN?8gy詬ƢS':\#]nrA?qsβCq5yxOփ6~~ rӇHҁX^F}1W7~yKQ*ũq+^TN9hMb_ǧ|#j1(?J&#IYDs hA y
z{i6ΤnΝqp
3`}}\v䆪pRSIFKvFcq.+
sw~=C*]tn~ts513ygdZa#<|ƹ3[@zZue+yєD<.8Ut3hBd%. tAfl;KЇ`ƃ0&\)"z<5rj
e&Jq|
_sYlj+"+سp.tS[E+!ZF?vs՚wSxd]ps{'R:yFHtdwM
y ̒ro vYY* U"k27k&4gٞuřc6ng{+:sq>3wLoRS
O5!UHDK|>{$=RZ4+'*u!'Uz/CNL{/psֽ~Lَ$tuUZ^lOJЏZ#u]iaZ8uZ+MùVW{'hψ.k[ .L/[ѫPRw(݄r*/Uv
7=WAAH:P7uumeίVrite-ìjF/'P,HSTnV,%%C;h;.6Q75
7
pE%
g1v7pr}
~+j8c9H
ޟdUTYQ[E*dN^7
3X3NI)bii[gWM())rtnfu,g~BW}|qKFb?ֲ}꒜fAvyіmRuWt /=ֱ7TrR`^猥r]s;VNȞQ.+kw?}g?4W]8#;oKk[2J%Xұ}O>}i}]wEN.}ßx:ÿgW;uSVs=!(@ t
endstream
endobj
77 0 obj
<>
endobj
111 0 obj
<>stream
HUiTg>#IˌiES7
A" $, @ $ #c;V\JkL[Ω/}%j̙sy{}ssyc10-,4eQ|Ob$1U~3à}1z9iڀu ZAg8=\|}1#kZNmfJET g?rV
~k+\r6%xR'svf2D /lJOsD<1Oc˾s9Qb2O(:3i&i;'1#yPIb~2?Q}30[0f1\XUc3ub1l[g
pF!ecz;_؇k"33:AOzَjǿ̚5+59˹ilYYDuIr5ލ6>Ͻ
/HQqgyzOoO6/9,[H%~Q^vvH$7V+$ j@#7PVd1Yi4~;:掎lP-c[|:!/N|yd!EB:rC }l'{rk|X#v! rUT6&rfr<"Y&+7֕ FKQ^-gFE+H=#6CR|yX*Hpz!,dpYF2!o-s^'/og}$ d2ܝƛ
;q SK1 ,P1B韨}e9EtYq"qiBqJx5V/8W*ɈӚ%R/Iquo;,9TI,k8Q*UѪjUzë@:W'pk@Ͱg2i)O
:hy/c $JP
e3&<'X!87p:ʥT ~De^m۷3ձ
b_P*|C~[
l-84zG